Brief Communication

Clinical and positron emission tomography of Parkinson's disease caused by LRRK2

  1. Dena G. Hernandez MS1,
  2. Coro Paisán-Ruíz BS1,2,
  3. Aideen McInerney-Leo MS3,
  4. Shushant Jain BSC1,4,5,
  5. Andreas Meyer-Lindenberg BA6,
  6. E. Whitney Evans BA1,
  7. Karen F. Berman MD6,
  8. Janel Johnson BA1,
  9. Georg Auburger MD7,
  10. Alejandro A. Schäffer PhD8,
  11. Grisel J. Lopez MD3,
  12. Robert L. Nussbaum MD3,
  13. Andrew B. Singleton PhD1,*

Article first published online: 24 FEB 2005

DOI: 10.1002/ana.20401

Issue

Annals of Neurology

Annals of Neurology

Volume 57, Issue 3, pages 453–456, March 2005

Additional Information

How to Cite

Hernandez, D. G., Paisán-Ruíz, C., McInerney-Leo, A., Jain, S., Meyer-Lindenberg, A., Evans, E. W., Berman, K. F., Johnson, J., Auburger, G., Schäffer, A. A., Lopez, G. J., Nussbaum, R. L. and Singleton, A. B. (2005), Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol., 57: 453–456. doi: 10.1002/ana.20401

Author Information

  1. 1

    Molecular Genetics Unit, National Institute on Aging, National Institutes of Health, Department of Health and Human Services, Porter Neuroscience Research Center, Bethesda, MD

  2. 2

    Unitat de Genètica Molecular, Departament de Genòmica i Proteòmica, Institut de Biomedicina de València–Consejo Superior de Investigaciones Científicas, València, Spain

  3. 3

    Genetic Diseases Research Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  4. 4

    Department of Molecular Neuroscience, Institute of Neurology, London, United Kingdom

  5. 5

    Reta Lila Weston Insitute of Neurological Sciences, London, United Kingdom

  6. 6

    Unit on Integrative Neuroimaging; Genes, Cognition and Psychosis Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD

  7. 7

    Molecular Genetics Section, Clinic for Neurology, JW Goethe University, Frankfurt, Germany

  8. 8

    National Center for Biotechnology Information, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

*Laboratory of Neurogenetics, National Institutes on Aging, NIH, Building 10, Room 6C103, MSC 1589, 9000 Rockville Pike, Bethesda, MD 20892

Publication History

  1. Issue published online: 24 FEB 2005
  2. Article first published online: 24 FEB 2005
  3. Manuscript Accepted: 21 DEC 2004
  4. Manuscript Revised: 20 DEC 2004
  5. Manuscript Received: 8 NOV 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (356K)

Abstract

We have recently identified mutations in a gene leucine-rich repeat kinase–2 (LRRK2), which cause autosomal dominant Parkinson's disease. Here, we describe two families with autosomal dominant Parkinson's disease caused by a LRRK2 G2019S mutation. We present here a clinical description of patients, including 6-18F-fluoro-L-dopa positron emission tomography and discuss the potential implications of this mutation, which alters a conserved residue in a domain required for kinase activation. Ann Neurol 2005;57:453–456

View Full Article (HTML) Get PDF (356K)